Figure 5

In-vivo effects of JAI-51 on mice bearing subcutaneous GL26 xenografts. (A) Tumour onset and progression and (B) Mean tumour volumes, in JAI-51 treated GL26 xenografted mice. Control: untreated mice (n = 16), schedule 1: mice treated 3 times a week with 32 mg/kg JAI-51 (n = 10); schedule 2: mice treated once a week with 96 mg/kg JAI-51 (n = 6). Results are from one representative experiment out of two. For (B) statistical analysis using Dunn's Multiple Comparison Test following one-way ANOVA showed that the mean tumour volumes were significantly lower in the group treated with schedule 2 compared to the control group throughout the length of the experiment (P < 0.05). (C, upper panel) chromatogram of JAI-51 in the tumours of mice treated with schedule 2, an hour and a half before sacrifice. (D, upper panel) chromatogram of brain homogenates from JAI-51 treated mice. As controls, known amounts of JAI-51 were analyzed in the same experimental conditions (C and D, lower panels).